Adamis pharmaceuticals announces tempol reduces lung inflammation in the covid-19 challenged hamster model

San diego, march 15, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) ("company") announced today that in studies conducted at galveston national laboratory (gnl), university of texas medical branch (utmb) at galveston, hamsters challenged with the virus that causes covid-19 (sars-cov-2), resulted in decreased inflammation in the lungs of animals treated with tempol compared to controls. this is the first data demonstrating that tempol, a novel antioxidant, can reduce inflammation in animals given the virus (sars-cov-2) that causes covid-19. the group plans on submitting the publication to a peer review journal.
ADMP Ratings Summary
ADMP Quant Ranking